SI1248804T2 - Rekombinantna protitelesa usmerjena proti humanemu interlevkinu-1 beta - Google Patents

Rekombinantna protitelesa usmerjena proti humanemu interlevkinu-1 beta

Info

Publication number
SI1248804T2
SI1248804T2 SI200130698T SI200130698T SI1248804T2 SI 1248804 T2 SI1248804 T2 SI 1248804T2 SI 200130698 T SI200130698 T SI 200130698T SI 200130698 T SI200130698 T SI 200130698T SI 1248804 T2 SI1248804 T2 SI 1248804T2
Authority
SI
Slovenia
Prior art keywords
beta
recombinant antibodies
human interleukin
interleukin
human
Prior art date
Application number
SI200130698T
Other languages
English (en)
Slovenian (sl)
Other versions
SI1248804T1 (sl
Inventor
Hermann Gram
Padova Franco E Di
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9884137&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI1248804(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of SI1248804T1 publication Critical patent/SI1248804T1/sl
Publication of SI1248804T2 publication Critical patent/SI1248804T2/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
SI200130698T 2000-01-21 2001-01-19 Rekombinantna protitelesa usmerjena proti humanemu interlevkinu-1 beta SI1248804T2 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0001448.0A GB0001448D0 (en) 2000-01-21 2000-01-21 Organic compounds
EP01905671A EP1248804B2 (en) 2000-01-21 2001-01-19 Recombinant antibodies to human interleukin-1 beta
PCT/EP2001/000591 WO2001053353A2 (en) 2000-01-21 2001-01-19 Recombinant antibodies to human interkleukin-1 beta

Publications (2)

Publication Number Publication Date
SI1248804T1 SI1248804T1 (sl) 2007-06-30
SI1248804T2 true SI1248804T2 (sl) 2010-04-30

Family

ID=9884137

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200130698T SI1248804T2 (sl) 2000-01-21 2001-01-19 Rekombinantna protitelesa usmerjena proti humanemu interlevkinu-1 beta

Country Status (33)

Country Link
US (4) US20030124617A1 (https=)
EP (1) EP1248804B2 (https=)
JP (2) JP3978338B2 (https=)
KR (1) KR100697126B1 (https=)
CN (1) CN1395581B (https=)
AR (1) AR027253A1 (https=)
AT (1) ATE346868T1 (https=)
AU (1) AU772949B2 (https=)
BR (1) BR0107661A (https=)
CA (1) CA2396212C (https=)
CO (1) CO5261584A1 (https=)
CY (1) CY1107989T1 (https=)
CZ (1) CZ302738B6 (https=)
DE (1) DE60124863T3 (https=)
DK (1) DK1248804T4 (https=)
ES (1) ES2274865T5 (https=)
GB (1) GB0001448D0 (https=)
HK (1) HK1050013A1 (https=)
HU (1) HUP0204156A3 (https=)
IL (2) IL150551A0 (https=)
MX (1) MXPA02007091A (https=)
MY (1) MY155269A (https=)
NO (1) NO329816B1 (https=)
NZ (1) NZ519936A (https=)
PE (1) PE20011219A1 (https=)
PL (1) PL207642B1 (https=)
PT (1) PT1248804E (https=)
RU (1) RU2264413C2 (https=)
SI (1) SI1248804T2 (https=)
SK (1) SK288054B6 (https=)
TR (1) TR200201780T2 (https=)
WO (1) WO2001053353A2 (https=)
ZA (1) ZA200205659B (https=)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0001448D0 (en) * 2000-01-21 2000-03-08 Novartis Ag Organic compounds
KR100919593B1 (ko) 2000-06-29 2009-09-29 아보트 러보러터리즈 이중 특이성 항체 및 이의 제조 방법 및 이를 포함하는 조성물
GB0020685D0 (en) 2000-08-22 2000-10-11 Novartis Ag Organic compounds
CA2474616A1 (en) * 2002-01-28 2003-08-07 Medarex, Inc. Human monoclonal antibodies to prostate specific membrane antigen (psma)
GB0303337D0 (en) 2003-02-13 2003-03-19 Celltech R&D Ltd Biological products
ATE491953T1 (de) * 2003-09-15 2011-01-15 Oklahoma Med Res Found Verfahren zur verwendung von cytokintests zur diagnose, behandlung und beurteilung von ankyloider spondylitis
DK2270045T3 (en) 2004-02-06 2015-04-07 Univ Massachusetts ANTIBODIES AGAINST CLOSTRIDIUM DIFFICILE TOXINES AND APPLICATIONS THEREOF
EP2361933A3 (en) * 2005-01-26 2012-05-02 Amgen Fremont Inc. Antibodies against interleukin-1 beta
JO3058B1 (ar) * 2005-04-29 2017-03-15 Applied Molecular Evolution Inc الاجسام المضادة لمضادات -اي ال-6,تركيباتها طرقها واستعمالاتها
HUE029021T2 (en) * 2005-06-21 2017-02-28 Xoma (Us) Llc IL-1beta-binding antibodies and fragments thereof
PL1940465T3 (pl) * 2005-10-26 2013-01-31 Novartis Ag Nowe zastosowanie przeciwciał anty-IL-1beta
HUE034269T2 (en) 2005-12-29 2018-02-28 Janssen Biotech Inc Human anti-IL-23 antibodies, preparations, methods and applications
US7943328B1 (en) 2006-03-03 2011-05-17 Prometheus Laboratories Inc. Method and system for assisting in diagnosing irritable bowel syndrome
KR20110079922A (ko) * 2006-04-14 2011-07-11 노파르티스 아게 안과 장애 치료를 위한 ｉｌ－1 항체의 용도
US20080085524A1 (en) * 2006-08-15 2008-04-10 Prometheus Laboratories Inc. Methods for diagnosing irritable bowel syndrome
EP3124045A3 (en) 2006-12-20 2017-05-03 Xoma (Us) Llc Treatment of il-1 beta related diseases
EP2114443A4 (en) * 2006-12-29 2011-08-10 Abbott Lab IL-1A / IL-1B ANTIBODY WITH DOUBLE SPECIFICITY
CA2679400A1 (en) 2007-02-28 2008-09-04 Schering Corporation Combination therapy for treatment of immune disorders
CN104873972A (zh) * 2007-05-29 2015-09-02 诺华股份有限公司 抗IL-1β治疗的新适应症
SI2391650T1 (sl) 2007-12-20 2015-03-31 Xoma (Us) Llc Postopki za zdravljenje protina
CA2727171A1 (en) * 2008-06-06 2009-12-10 Xoma Technology Ltd. Methods for the treatment of rheumatoid arthritis
JP2012502058A (ja) 2008-09-05 2012-01-26 ゾーマ テクノロジー リミテッド β細胞機能の改善のための方法
SI2493922T1 (sl) 2009-10-26 2017-06-30 F. Hoffmann-La Roche Ag Postopek za proizvodnjo glikoziliranega imunoglobulina
BR112012028557A2 (pt) 2010-05-07 2019-09-24 Xoma Technology Ltd. uso de um anticorpo anti-il-1b ou de fragmentos de ligação do mesmo.
DE102010033565B4 (de) * 2010-07-27 2012-06-21 Tetec Tissue Engineering Technologies Ag Marker zur Bestimmung von Chondrozyten
SMT201700023T1 (it) 2010-08-02 2017-03-08 Regeneron Pharma Topi che producono proteine leganti vl
CN103328511B (zh) 2010-09-10 2016-01-20 埃派斯进有限公司 抗-IL-1β抗体及其使用方法
ME02106B (me) * 2011-02-25 2015-10-20 Regeneron Pharma Miševi sa adam6
HUE047278T2 (hu) 2011-08-05 2020-04-28 Regeneron Pharma Humanizált univerzális könnyûláncú egerek
DE102011083595A1 (de) 2011-09-28 2013-03-28 Bayer Pharma AG Inhibition der Wirkung von Interleukin 1 beta zur Behandlung der Endometriose
WO2013096516A1 (en) 2011-12-19 2013-06-27 Xoma Technology Ltd. Methods for treating acne
SG10201605675WA (en) 2011-12-20 2016-09-29 Regeneron Pharma Humanized light chain mice
LT2814843T (lt) 2012-02-13 2020-09-25 Agency For Science, Technology And Research ŽMOGAUS MONOKLONINIAI ANTIKŪNAI, NEUTRALIZUOJANTYS IL-1ß
ME03551B (me) 2012-06-12 2020-07-20 Regeneron Pharma Humanizovane nehumane živoтinje sa ograničenim lokusima imunoglobulinskog тeškog lanca
AU2015231025A1 (en) 2014-03-21 2016-09-15 Regeneron Pharmaceuticals, Inc. Vl antigen binding proteins exhibiting distinct binding characteristics
CA3124228C (en) 2014-03-21 2024-05-14 Regeneron Pharmaceuticals, Inc. Non-human animals that make single domain binding proteins
CA2979702A1 (en) 2015-03-19 2016-09-22 Regeneron Pharmaceuticals, Inc. Non-human animals that select for light chain variable regions that bind antigen
MX2020009265A (es) 2018-03-05 2020-10-01 Janssen Biotech Inc Metodos para tratar la enfermedad de crohn con un anticuerpo especifico anti-il23.
CN110818793A (zh) 2018-08-14 2020-02-21 中山康方生物医药有限公司 抗IL-1β的抗体、其药物组合物及其用途
IL283192B2 (en) 2018-11-20 2025-10-01 Janssen Biotech Inc A safe and effective method for treating psoriasis with a specific anti-IL-23 antibody
JP7805788B2 (ja) 2019-05-23 2026-01-26 ヤンセン バイオテツク，インコーポレーテツド Ｉｌ－２３及びｔｎｆアルファに対する抗体の併用療法による炎症性腸疾患の治療方法
IL298389A (en) 2020-05-21 2023-01-01 Janssen Biotech Inc Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha
CN116063489B (zh) * 2022-10-21 2026-01-30 杭州靶向食品科技有限公司 一种治疗痛风的单克隆抗体及其相应的组合物
CN121511262A (zh) 2023-06-28 2026-02-10 北京哲源科技有限责任公司 靶向pd-l1和il-1的双特异性抗体及其用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4772685A (en) 1985-10-02 1988-09-20 Merck & Co., Inc. Immunogenic peptides of human interleukin-1 and the corresponding anti-peptide antibodies
US4935343A (en) * 1986-08-08 1990-06-19 Syntex (U.S.A.) Inc. Monoclonal antibodies for interleukin-1β
FR2640146B1 (fr) * 1988-12-08 1993-12-24 Commissariat A Energie Atomique Anticorps monoclonaux anti-interleukines 1(alpha) et 1(beta), leur procede de production et applications desdits anticorps a la detection des interleukines 1(alpha) et 1(beta) et en therapeutique
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
JP3714683B2 (ja) * 1992-07-30 2005-11-09 生化学工業株式会社 抗リウマチ剤
US5429614A (en) 1993-06-30 1995-07-04 Baxter International Inc. Drug delivery system
WO1995001997A1 (en) * 1993-07-09 1995-01-19 Smithkline Beecham Corporation RECOMBINANT AND HUMANIZED IL-1β ANTIBODIES FOR TREATMENT OF IL-1 MEDIATED INFLAMMATORY DISORDERS IN MAN
US6051228A (en) 1998-02-19 2000-04-18 Bristol-Myers Squibb Co. Antibodies against human CD40
GB0001448D0 (en) * 2000-01-21 2000-03-08 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
ES2274865T3 (es) 2007-06-01
MXPA02007091A (es) 2002-12-13
CA2396212A1 (en) 2001-07-26
JP2003520595A (ja) 2003-07-08
RU2002121649A (ru) 2004-03-10
US7491392B2 (en) 2009-02-17
AU3369701A (en) 2001-07-31
IL150551A0 (en) 2003-02-12
US20090232803A1 (en) 2009-09-17
CO5261584A1 (es) 2003-03-31
DK1248804T4 (da) 2010-04-06
SK10352002A3 (sk) 2003-03-04
KR100697126B1 (ko) 2007-03-20
SK288054B6 (sk) 2013-03-01
GB0001448D0 (en) 2000-03-08
US20030124617A1 (en) 2003-07-03
AR027253A1 (es) 2003-03-19
PE20011219A1 (es) 2001-12-17
JP2007097598A (ja) 2007-04-19
HUP0204156A2 (hu) 2003-03-28
US20060251660A1 (en) 2006-11-09
HK1050013A1 (zh) 2003-06-06
WO2001053353A3 (en) 2002-04-04
EP1248804B1 (en) 2006-11-29
PL207642B1 (pl) 2011-01-31
CN1395581A (zh) 2003-02-05
JP3978338B2 (ja) 2007-09-19
CZ302738B6 (cs) 2011-10-12
DE60124863D1 (de) 2007-01-11
NO20023266D0 (no) 2002-07-05
CY1107989T1 (el) 2013-09-04
MY155269A (en) 2015-09-30
BR0107661A (pt) 2002-11-19
AU772949B2 (en) 2004-05-13
DE60124863T2 (de) 2007-04-26
PT1248804E (pt) 2007-02-28
ATE346868T1 (de) 2006-12-15
KR20020073178A (ko) 2002-09-19
NO329816B1 (no) 2010-12-27
IL150551A (en) 2010-11-30
DK1248804T3 (da) 2007-02-26
SI1248804T1 (sl) 2007-06-30
WO2001053353A2 (en) 2001-07-26
DE60124863T3 (de) 2010-05-20
PL356297A1 (en) 2004-06-28
ZA200205659B (en) 2003-12-31
HUP0204156A3 (en) 2005-09-28
US20110182894A1 (en) 2011-07-28
TR200201780T2 (tr) 2003-01-21
CN1395581B (zh) 2010-10-13
NZ519936A (en) 2004-02-27
CZ20022531A3 (cs) 2002-10-16
EP1248804B2 (en) 2009-12-02
ES2274865T5 (es) 2010-04-19
CA2396212C (en) 2013-04-02
RU2264413C2 (ru) 2005-11-20
NO20023266L (no) 2002-08-28
EP1248804A2 (en) 2002-10-16

Similar Documents

Publication Publication Date Title
ZA200205659B (en) Recombinant antibodies to human interleukin-1 beta
NL300427I1 (en) Antibodies to human IL-1 beta
AU4835001A (en) Antibodies to human cd154
AU8390301A (en) Antibodies to human MCP-1
EP1156924A4 (en) HIGH PERFORMANCE SUCTIONLY STRUCTURE
PT1163271E (pt) Anticorpos il-18 recombinantes e a sua utilização
IL161705A0 (en) Human monoclonal antibodies to dendritic cells
IL185764A0 (en) Antibody to cytokine receptor zalpha11
EP1423432A4 (en) ANTIBODIES TO INTERLEUKIN 1 BETA (IL-1BETA)
EP1151006A4 (en) HUMAN G PROTEIN TORQUE RECEPTOR
AU7522401A (en) Non-agonistic antibodies to human gp39, compositions containing, and therapeuticuse thereof
IL129273A0 (en) Antibodies to placental protein 13
TW450361U (en) Egg collector for parasite egg in feces
GB2364057A8 (en) G protein coupled receptor
EP1365027A4 (en) FUSION PROTEINS AS FAS-LIGAND
GB0011269D0 (en) Protein over expression
AU2001245815A1 (en) Human immune response proteins
EP1152059A4 (en) NOVEL CYTOKINE RECEPTOR TYPE PROTEIN
TW435091U (en) Underpants with dividing structure
GB0016824D0 (en) Human monoclonal antibodies
GB0017139D0 (en) Human monoclonal antibodies
GB0024673D0 (en) Therapeutic antibodies
GB9927698D0 (en) Therapeutic antibody
GB0027675D0 (en) Protein Expression
GB0004695D0 (en) Protein expression